Vascular smooth muscle cell microparticles and coronary no-reflow: another piece of the puzzle?

Robert V. Kelly; George A. Stouffer

doi:10.1160/TH05-08-0570

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(04): 693-694
DOI: 10.1160/TH05-08-0570

Editorial Focus

Schattauer GmbH

Vascular smooth muscle cell microparticles and coronary no-reflow: another piece of the puzzle?

Authors

Robert V. Kelly

¹Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina, USA
George A. Stouffer

¹Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina, USA

²Division of Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina, USA

Abstract

Full Text

References

References
1 Kelly RV, Cohen MG, Runge MS, Stouffer GA. The no-reflow phenomenon in coronary arteries. J Thromb Haemost 2004; 2: 1903-7.
2 Ito H, Maruyama A, Iwakura K. et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-8.
3 Abbo KM, Dooris M, Glazier S. et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995; 75: 778-82.
4 Kotani J, Nanto S, Mintz G S. et al. Plaque gruel of atheromatous coronary lesion may contribute to the noreflow phenomenon in patients with acute coronary syndrome. Circulation 2002; 106: 1672-7.
5 Essayagh S, Brisset A-C, Terrisse A-D. et al. Microparticles from apoptotic vascular smooth muscle cells induce endothelial dysfunction, a phenomenon prevented by β3 integrin antagonists. Thromb Haemost 2005; 94: 853-8.
6 Reverter JC, Beguin S, Kessels H. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863-74.
7 Goto S, Tamura N, Li M. et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-30.
8 Morel O, Hugel B, Jesel L. et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-26.
9 Aymong ED, Curtis MJ, Youssef M. et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002; 105: 2981-5.
10 Tcheng JE, Kandzari DE, Grines C L. et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003; 108: 1316-23.
11 Boulanger CM, Scoazec A, Ebrahimian T. et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-52.
12 Brisset AC, Terrisse AD, Dupouy D. et al. Shedding of active tissue factor by aortic smooth muscle cells (SMCs) undergoing apoptosis. Thromb Haemost 2003; 90: 511-8.
13 Schecter AD, Spirn B, Rossikhina M. et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000; 87: 126-32.